The content on this site is intended for healthcare professionals only
Dr Hagop Kantarjian explains how the introduction of tyrosine kinase inhibitors (TKIs) such as imatinib, bosutinib, nilotinib and dasatinib have produced a functional cure in many patients with chronic myeloid leukaemia and discusses what clinicians should consider when deciding between these drugs.
A minority of patients show resistance to these drugs; including those with the T315I mutation, however, Phase I results have suggested that these patients can be effectively treated with ponatinib. Dr Kantarjian concludes by discussing the financial repercussions of the indefinite treatment required for a functional cure and explains what research is being done to find new drugs which produce a full molecular cure.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Addressing the rise of multiple myeloma in Rwanda
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
